Please use this identifier to cite or link to this item:
|Title:||Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease|
|Abstract:||Multiple sclerosis (MS) exhibits many of the hallmarks of an inflammatory autoimmune disorder including breakdown of the blood-brain barrier (BBB), the recruitment of lymphocytes, microglia, and macrophages to lesion sites, the presence of multiple lesions, generally being more pronounced in the brain stem and spinal cord, the predominantly perivascular location of lesions, the temporal maturation of lesions from inflammation through demyelination, to gliosis and partial remyelination, and the presence of immunoglobulin in the central nervous system and cerebrospinal fluid. Lymphocytes activated in the periphery infiltrate the central nervous system to trigger a local immune response that ultimately damages myelin and axons. Pro-inflammatory cytokines amplify the inflammatory cascade by compromising the BBB, recruiting immune cells from the periphery, and activating resident microglia. inflammation-associated oxidative burst in activated microglia and macrophages plays an important role in the demyelination and free radical-mediated tissue injury in the pathogenesis of MS. The inflammatory environment in demyelinating lesions leads to the generation of oxygen- and nitrogen-free radicals as well as proinflammatory cytokines which contribute to the development and progression of the disease. Inflammation can lead to oxidative stress and vice versa. Thus, oxidative stress and inflammation are involved in a self-perpetuating cycle. " 2013 Genaro G. Ortiz et al.",,,,,,"10.1155/2013/708659",,,"http://hdl.handle.net/20.500.12104/42086","http://www.scopus.com/inward/record.url?eid=2-s2.0-84885601121&partnerID=40&md5=dcb5efd2e9a67811eae1f5fdee432f54",,,,,,,,"Clinical and Developmental Immunology",,,,"2013",,"Scopus|
WOS",,,,,,,,,,,,"Immunology and oxidative stress in multiple sclerosis: Clinical and basic approach",,"Review" "43862","123456789/35008",,,,"Velázquez Rivera, M. E.",,"1994",,,,,,,,,,,"http://hdl.handle.net/20.500.12104/42083",,,"Español",,,,"1",,"#N/A",,"273-279",,,,"CLASE",,,,,,,,"Ideología",,,,"El pensamiento de libertad en francisco javier clavigero",,"journalArticle" "43882","123456789/35008",,"Jiménez-Ochoa, I., CINVESTAV-IPN Unidad Guadalajara, Prol. Lopez Mateos Sur 590 C.P., 45090 Guadalajara, Jal., Mexico; Begovich, O., CINVESTAV-IPN Unidad Guadalajara, Prol. Lopez Mateos Sur 590 C.P., 45090 Guadalajara, Jal., Mexico; Ramírez-Treviño, A., CINVESTAV-IPN Unidad Guadalajara, Prol. Lopez Mateos Sur 590 C.P., 45090 Guadalajara, Jal., Mexico; Aguirre-Salas, L.I., Depto. de Ingenieria CUCSUR, U.deG Av. Independencia Nal. 151 CP, 48900 Autlan de Navarro, Jal, Mexico",,"Jimenez-Ochoa, I.
Aguirre-Salas, L.I.",,"2003",,"This paper is concerned with Multiagent System (MAS). In particular, the design of a function that generates beliefs in an agent using the Belief-Desire-Intention (BDI) architecture is presented. This work is developed in the Discrete Event Systems (DES) context, since they include a broad class of systems like Flexible Manufacturing Systems that can be modeled as Interpreted Petri Net (IPN). The mathematical analysis used in this paper allows to determine, using lineal algebra concepts, when the belief will tend to a fact as new information is perceived by the agent.",,,,,,,,,"http://hdl.handle.net/20.500.12104/42103","http://www.scopus.com/inward/record.url?eid=2-s2.0-0242661357&partnerID=40&md5=7728e647835b7b2b66712091dab50586",,,,,,,,"Proceedings of the IEEE International Conference on Systems, Man and Cybernetics",,"286
291",,"1",,"Scopus",,,,,,"BDI architecture; IPN; Observer",,,,,,"Implementing BDI agents using Petri Nets",,"Conference Paper" "43877","123456789/35008",,"Ludwiczek, O., Academic Teaching Hospital Hall, Tyrol, Austria; Vannier, E., Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, United States; Moschen, A., Christian Doppler Research Laboratory for Gut Inflammation, Division of Gastroenterology and Hepatology, Medical University Innsbruck, Austria; Salazar-Montes, A., PhD Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara (Sierra Mojada #950 Col. Independencia), Guadalajara Jalisco, Mexico; Borggraefe, I., Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, United States; Gabay, C., Division of Rheumatology, University Hospital, Geneva, Switzerland; Enrich, B., Christian Doppler Research Laboratory for Gut Inflammation, Division of Gastroenterology and Hepatology, Medical University Innsbruck, Austria; Kaser, A., Christian Doppler Research Laboratory for Gut Inflammation, Division of Gastroenterology and Hepatology, Medical University Innsbruck, Austria; Siegmund, B., Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO, United States; Dinarello, C., Division of Rheumatology, University Hospital, Geneva, Switzerland; Tilg, H., Academic Teaching Hospital Hall, Tyrol, Austria, Christian Doppler Research Laboratory for Gut Inflammation, Division of Gastroenterology and Hepatology, Medical University Innsbruck, Austria, Christian Doppler Research Laboratory for Gut Inflammation, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria",,"Ludwiczek, O.
Tilg, H.",,"2008",,"Objective. To assess the production of the endogenous IL-1 modulators IL-1 receptor antagonist (IL-1Ra), type I and II soluble IL-1 receptors (IL-1sRI and II) in patients with chronic liver disease (CLD). Material and methods. Plasma levels of IL-1beta (IL-1?) and IL-1 modulators were assessed in 126 CLD patients and 39 healthy controls. IL-1sRII was also measured in the supernatants of primary hepatocyte cultures. Results. Plasma IL-1sRI and IL-1Ra levels were significantly higher in cirrhotic CLD patients than in non-cirrhotic CLD patients and in controls. Levels did not depend on the etiology of CLD. Likewise, plasma IL-1? levels were elevated in CLD patients compared with those in controls. In contrast, IL-1sRII levels did not differ between CLD patients and controls. Cultures of human primary hepatocytes showed that IL-1sRII is induced by IL-1?, but not IL-6. Conclusions. In cirrhotic CLD patients elevated plasma IL-1? is not counteracted by endogenous levels of IL-1sRII, whereas high IL-1sRI is expected to neutralize the naturally occurring antagonist IL-1Ra, resulting in a dysregulation of the IL-1 system that might enhance pro-inflammatory activity of IL-1. " 2008 Informa UK Ltd.
|Appears in Collections:||Producción científica UdeG|
Files in This Item:
There are no files associated with this item.
Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.